SLSBio(Specialty Lab Solution Bio)에스엘에스바이오

SLSBio is still loss-making on a trailing basis, with revenue falling sharply and delisting-related filings in the latest records.

SLSBio runs pharmaceutical quality control testing, new drug development support and in vitro diagnostic kits from South Korea. Trailing twelve-month revenue to H1 2026 was about ₩2.9B, with an operating loss near ₩5.1B and a net loss near ₩5.6B. A news item from October 19, 2026 says testing revenue is recovering and new businesses are expanding, but the data does not show quarterly figures to confirm that.

What stands out

• Revenue fell from ₩10.8B in 2022 to ₩4.0B in 2025, and trailing revenue to H1 2026 is ₩2.9B.
• Operating margin was -175.1% on a trailing basis, compared with a profitable 2023 and 2024 (operating margins of 11.4% and 3.4%).
• Cash of ₩1.8B exceeds borrowings of ₩470M, but free cash flow was about -₩4.8B on a trailing basis.
• The filings list includes several 'Delisting' entries dated August 31 and October 23, 2026, plus a March 2026 notice on listing eligibility review; the data does not explain these entries.
• Foreign ownership is 1.1% and unchanged over 60 days, and there is no dividend.

What to watch

• Whether the delisting-related filings from October 2026 lead to a change in trading status; the data does not state the outcome.
• The next quarterly or annual results, to see whether revenue recovery and the loss trend continue.
• The status of the improvement plan submitted in September 2026, which the data names but does not detail.